89 related articles for article (PubMed ID: 19945447)
1. Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.
Inoue N; Takai S; Jin D; Okumura K; Okamura N; Kajiura M; Yoshikawa S; Kawamura N; Tamai H; Miyazaki M
Clin Chim Acta; 2010 Feb; 411(3-4):267-9. PubMed ID: 19945447
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory profiles of captopril on matrix metalloproteinase-9 activity.
Yamamoto D; Takai S; Miyazaki M
Eur J Pharmacol; 2008 Jul; 588(2-3):277-9. PubMed ID: 18501888
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters.
Takai S; Yamamoto D; Jin D; Inagaki S; Yoshikawa K; Tanaka K; Miyazaki M
Eur J Pharmacol; 2007 Jul; 568(1-3):231-3. PubMed ID: 17512521
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats.
Tanaka H; Takai S; Jin D; Furubayashi K; Inoue N; Kajimoto Y; Miyatake S; Kuroiwa T; Miyazaki M
Hypertens Res; 2007 May; 30(5):469-75. PubMed ID: 17587759
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-9/tissue inhibitors of metalloproteinase-1 expression and atrial structural remodeling in a dog model of atrial fibrillation: inhibition with angiotensin-converting enzyme.
Zhang W; Zhong M; Yang GR; Li JP; Guo C; Wang Z; Zhang Y
Cardiovasc Pathol; 2008; 17(6):399-409. PubMed ID: 18706834
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
[TBL] [Abstract][Full Text] [Related]
8. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.
Liebetrau M; Burggraf D; Wunderlich N; Jäger G; Linz W; Hamann GF
Neurosci Lett; 2005 Mar; 376(3):205-9. PubMed ID: 15721222
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease.
Lau AC; Duong TT; Ito S; Yeung RS
Arthritis Rheum; 2009 Jul; 60(7):2131-41. PubMed ID: 19565485
[TBL] [Abstract][Full Text] [Related]
10. Effect of cadmium and captopril on serum angiotensin converting enzyme activity in rats.
Puri VN
Indian Heart J; 1997; 49(3):297-9. PubMed ID: 9291654
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the renin-angiotensin system improves the early stages of liver regeneration and liver function.
Koh SL; Ager E; Malcontenti-Wilson C; Muralidharan V; Christophi C
J Surg Res; 2013 Jan; 179(1):66-71. PubMed ID: 23110972
[TBL] [Abstract][Full Text] [Related]
12. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy.
Yamamoto D; Takai S; Hirahara I; Kusano E
Clin Chim Acta; 2010 May; 411(9-10):762-4. PubMed ID: 20184869
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
14. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
15. Performance of two commonly used angiotensin-converting enzyme inhibition assays using FA-PGG and HHL as substrates.
Shalaby SM; Zakora M; Otte J
J Dairy Res; 2006 May; 73(2):178-86. PubMed ID: 16476177
[TBL] [Abstract][Full Text] [Related]
16. ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.
Sacco G; Mario B; Lopez G; Evangelista S; Manzini S; Maggi CA
Vascul Pharmacol; 2009; 50(5-6):166-70. PubMed ID: 19344651
[TBL] [Abstract][Full Text] [Related]
17. Captopril ameliorates the decreased Na+,K(+)-ATPase activity in the retina of streptozotocin-induced diabetic rats.
Ottlecz A; Bensaoula T
Invest Ophthalmol Vis Sci; 1996 Jul; 37(8):1633-41. PubMed ID: 8675407
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
[TBL] [Abstract][Full Text] [Related]
19. Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels.
Falcini F; Cerinic MM; Ermini M; Generini S; Lombardi A; Pignone A; Leoncini G; Tirassa P; Aloe L
J Rheumatol; 1996 Oct; 23(10):1798-802. PubMed ID: 8895162
[TBL] [Abstract][Full Text] [Related]
20. Effect of captopril and enalapril medication on the serum ACE test for sarcoidosis.
Lieberman J; Zakria F
Sarcoidosis; 1989 Sep; 6(2):118-23. PubMed ID: 2557660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
